Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

BACKGROUND: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non–small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pem...

全面介紹

Na minha lista:
書目詳細資料
發表在:N Engl J Med
Main Authors: Mok, T.S., Wu, Y.-L., Ahn, M.-J., Garassino, M.C., Kim, H.R., Ramalingam, S.S., Shepherd, F.A., He, Y., Akamatsu, H., Theelen, W.S.M.E., Lee, C.K., Sebastian, M., Templeton, A., Mann, H., Marotti, M., Ghiorghiu, S., Papadimitrakopoulou, V.A.
格式: Artigo
語言:Inglês
出版: 2016
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6762027/
https://ncbi.nlm.nih.gov/pubmed/27959700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1612674
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍